



PRESS RELEASE

OncoMethylome Sciences Capital Increase Update

Liege (Belgium) – December 19, 2008, 11:55 AM CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that the capital increase of EUR 8.4 million as announced on December 16, 2008, has been completed and that the 1,332,877 new shares will be admitted to trading on Euronext Brussels and Euronext Amsterdam on December 19, 2008. A prospectus relating to the admission to listing of these shares will be made available on the company's website as from December 19, 2008.

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC (a Johnson & Johnson company), LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, EXACT Sciences Corp., Merck KGaA, and Qiagen. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Philip Devine
Tel. +32 479 505 885
ir@oncomethylome.com
www.oncomethylome.com